Medifast (NYSE:MED) Director Purchases 43,150 Shares

Key Points

• Medifast Director Parsa Kiai purchased 43,150 shares at an average price of $12.26, investing $529,019 and increasing his direct ownership by 6.5% to 707,492 shares.
• Kiai also made three additional purchases in August, bringing his recent buying activity to more than 120,000 shares and signaling increased insider exposure.
• Medifast shares rose 1.2% to $12.31, while the company reported better-than-expected quarterly revenue and EPS; analysts nonetheless maintain a consensus “Reduce” rating with a $12.00 target price.

Medifast Inc (NYSE:MED - Get Free Report) Director Parsa Kiai bought 43,150 shares of Medifast stock in a transaction that occurred on Wednesday, August 26th. The shares were acquired at an average price of $12.26 per share, for a total transaction of $529,019.00. Following the completion of the transaction, the director directly owned 707,492 shares of the company's stock, valued at $8,673,851.92. This trade represents a 6.50% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Monday, August 24th, Parsa Kiai purchased 4,329 shares of Medifast stock. The shares were bought at an average cost of $12.00 per share, for a total transaction of $51,948.00.
• On Thursday, August 20th, Parsa Kiai bought 43,150 shares of Medifast stock. The shares were purchased at an average price of $11.60 per share, with a total value of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai acquired 29,337 shares of Medifast stock. The shares were acquired at an average price of $11.66 per share, with a total value of $342,069.42.

Medifast Stock Up 1.2%

Shares of MED stock traded up $0.15 during mid-day trading on Friday, reaching $12.31. The company's stock had a trading volume of 77,941 shares, compared to its average volume of 228,350. The firm has a market capitalization of $137.64 million, a PE ratio of -5.28 and a beta of 0.65. The company's 50 day simple moving average is $10.98 and its 200-day simple moving average is $11.09. Medifast Inc has a 12-month low of $9.22 and a 12-month high of $14.67.

Medifast (NYSE:MED - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.37. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.The company had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. As a group, research analysts anticipate that Medifast Inc will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Medifast

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets grew its stake in shares of Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer's stock worth $32,000 after purchasing an additional 1,187 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Medifast in the 3rd quarter valued at approximately $37,000. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Medifast in the 4th quarter valued at approximately $47,000. State of Wyoming acquired a new position in Medifast in the 4th quarter worth approximately $59,000. Finally, Ancora Advisors LLC acquired a new position in Medifast in the 2nd quarter worth approximately $75,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on MED. Zacks Research downgraded shares of Medifast from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Weiss Ratings upgraded Medifast from a "sell (e+)" rating to a "sell (d)" rating in a research note on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Medifast presently has an average rating of "Reduce" and a consensus target price of $12.00.

About Medifast

Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source